NIPBL-AS1: A Promising Drug Target for Neurological Disorders

Target Name: NIPBL-DT

NCBI ID: G646719

NIPBL-DT

Other Name(s): NIPBL-AS1 | NIPBL divergent transcript | NIPBL-AS

NIPBL-AS1: A Promising Drug Target for Neurological Disorders

NIPBL-DT (NIPBL-AS1) is a protein that is expressed in the brain and is known for its role in the regulation of neuronal excitability. The NIPBL-AS1 protein has been shown to play a crucial role in the development and progression of various neurological disorders, including Alzheimer's disease. As a result, NIPBL-AS1 has emerged as a promising drug target for the development of new treatments for these disorders.

The NIPBL-AS1 protein is a member of the NIPBL family of proteins, which are known for their role in the regulation of intracellular signaling pathways. NIPBL-AS1 is predominantly expressed in the brain and is involved in the regulation of neuronal excitability. Its function is not well understood, but it is known to play a crucial role in the development and progression of various neurological disorders, including Alzheimer's disease.

One of the key functions of NIPBL-AS1 is its role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. NIPBL-AS1 has been shown to play a crucial role in the regulation of synaptic plasticity, with studies showing that it promotes the formation of new synapses and modulates the strength of existing synapses. This is important for the development and progression of various neurological disorders, as changes in synaptic plasticity are often a hallmark of these disorders.

In addition to its role in synaptic plasticity, NIPBL-AS1 has also been shown to play a role in the regulation of neurotransmitter release and neuroinflammation. Studies have shown that NIPBL-AS1 promotes the release of neurotransmitters, such as dopamine and glutamate, and is involved in the regulation of neuroinflammation. This is important for the development and progression of various neurological disorders, as changes in neurotransmitter release and neuroinflammation are often a hallmark of these disorders.

Given its role in the regulation of neuronal excitability and synaptic plasticity, NIPBL-AS1 is a promising drug target for the development of new treatments for various neurological disorders. Studies have shown that NIPBL-AS1 can be targeted with small molecules, such as those that can modulate its activity or interactions with other proteins. Additionally, researchers have been able to use techniques such as RNA interference and CRISPR/Cas9 to knockdown and activate NIPBL-AS1, providing further insight into its function.

In conclusion, NIPBL-AS1 is a protein that has been shown to play a crucial role in the regulation of neuronal excitability and synaptic plasticity. Its function is not well understood, but it is known to be involved in the development and progression of various neurological disorders, including Alzheimer's disease. As a result, NIPBL-AS1 has emerged as a promising drug target for the development of new treatments for these disorders. Further research is needed to fully understand the function of NIPBL-AS1 and to develop effective treatments for this promising drug target.

Protein Name: NIPBL Divergent Transcript

The "NIPBL-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NIPBL-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets